PROTA THERAPEUTICS PTY LTD
Paul Kelly has extensive work experience in the healthcare and biotechnology industries. Paul is currently the Founding Partner of OneVentures, a role they have held since 2009. In addition, they serve as a Board Member for Blade Therapeutics Pty Ltd, a Non-Executive Director for BiVACOR Inc and PROTA THERAPEUTICS PTY LTD, and a Member of the Board of Directors for the Garvan Institute of Medical Research.
Paul has also held leadership positions in various companies, including Chairman of Vaxxas Pty Ltd and Hatchtech Pty Ltd. Paul has worked as an Endocrinologist at St Vincents Hospital, Sydney. Paul has also served as a Non-Executive Director for Clinical Genomics, where they contributed to the development of diagnostic tests for colorectal cancer. Additionally, they were a Non-Executive Director for AgaMatrix until May 2020.
Paul Kelly attended the University of New South Wales (UNSW) from 1978 to 1983, where they obtained a degree in Medicine (MB BS [Hons]). Paul subsequently pursued further education at UNSW from 1987 to 1989, completing a degree in Genetic epidemiology, osteoporosis, twin studies (MD). Paul then went on to pursue a specialization in Endocrinology at the Royal Australasian College of Physicians, obtaining a degree in FRACP.
This person is not in any teams
PROTA THERAPEUTICS PTY LTD
Prota Therapeutics is an Australian, proprietary limited, privately-held biotech company established in 2016 to develop and commercialize novel combination probiotic allergen oral immunotherapy treatments. Prota holds an exclusive license to the patented probiotic food immunotherapy technology, developed at the MCRI. Series A funding of AUD $15mwas secured from OneVentures, a leading Australian venture capital investment firm (OneVentures' Healthcare Fund III) – including $5M from the Australian Commonwealth Government Biomedical Translation Fund – as well as private investment. This has enabled Prota to advance their clinical program, develop scalable cGMP product manufacturing processes, and initiate discussions with regulatory agencies in the lead up to a planned large-scale pivotal Phase 3 efficacy and safety study for the PRT100 peanut allergy treatment.